RIFERIMENTI BIBLIOGRAFICI

American Society of Clinical Oncology. (2015). The state of cancer care in America, 2015: a report by the American Society of Clinical Oncology. Journal of oncology practice, 11(2), 79-113.

Bittner, B., Richter, W., & Schmidt, J. (2018). Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs, 32(5), 425-440.

Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., ... & Cristofanilli, M. (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. Journal of clinical oncology, 23(16), 36763685.

Chevreul, K., Com-Ruelle, L., Midy, F., & Paris, V. (2004). Le développement des services de soins hospitaliers à domicile: éclairage des expériences australienne, britannique et canadienne. Questions d'économie de la santé, (91), 1-8.

Chini, C., Bascialla, L., Giaquinto, A., Magni, E., Gobba, S. M., Proserpio, I., ... & Pinotti, G. (2020). Homcology: Home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients. Supportive Care in Cancer, 1-7.

Cicchetti A, Coretti S, Di Brino E, Mascia D, Refolo P, Rolli FR, Rumi F, Sacchini D, Sacco F, Spagnolo AG. Mini HTA di rituximab e trastuzumab in formulazione sottocutanea, Working Paper Altems n. 1, 2017.

Cool, L., Vandijck, D., Debruyne, P., Desmedt, M., Lefebvre, T., Lycke, M., ... & Van Eygen, K. (2018). Organization, quality and cost of oncological home-hospitalization: A systematic review. Critical Reviews in Oncology/Hematology, 126, 145-153.

Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G; Panel members. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020 Oct;31(10):1320-1335.

Denys, H., Martinez-Mena, C. L., Martens, M. T., D’Hondt, R. G., Graas, M. P. L., Evron, E., ... & Van Steenberghe, M. M. (2020). Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. Breast cancer research and treatment, 181(1), 97.

Farfan-Portet, M., Alain, D., Lut, M., Francois, D., Mistiaen, P., & Gerkens, S. (2015). Implementation of hospital at home: orientations for Belgium. Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE).

George J, Shalansky SJ (2007) Predictors of refill non-adherence inpatients with heart failure. Br J Clin Pharmacol 63:488–493

Gianni, L., Dafni, U., Gelber, R. D., Azambuja, E., Muehlbauer, S., Goldhirsch, A., ... & Cameron, D. (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. The lancet oncology, 12(3), 236244.

Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X (2017) Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: safeher phase III study’s primary analysis of 2573 patients. Eur J Cancer 82:237–246.

Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., De Azambuja, E., Procter, M., Suter, T. M., ... & Dal Lago, L. (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. The Lancet, 382(9897), 1021-1028.

Halyard, M. Y., Pisansky, T. M., Dueck, A. C., Suman, V., Pierce, L., Solin, L., ... & Kutteh, L. (2009). Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. Journal of clinical oncology, 27(16), 2638.

Hoffmann, F., & Fröba, M. (2011). Vitalising porous inorganic silica networks with organic functions— PMOs and related hybrid materials. Chemical Society Reviews, 40(2), 608-620.

Jackisch, C., Harbeck, N., Huober, J., von Minckwitz, G., Gerber, B., Kreipe, H. H., ... & Schneeweiss, A. (2015). 14th St. Gallen International Breast Cancer Conference 2015: evidence, controversies, consensusprimary therapy of early breast cancer: opinions expressed by German experts. Breast care, 10(3), 211219.

Jacquin, J. P., Uwer, L., Savignoni, A., Ferrero, J. M., Lortholary, A., Solub, D., ... & Belkacemi, Y. (2020). Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study. The Breast, 49, 1-7.

Jung KH, Ataseven B, Verrill M, Pivot X, De Laurentiis M, Al-Sakaff N, Lauer S, Shing M, Gligorov J, Azim HA (2018) Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: subgroup analyses of safety and active medical conditions by body weight in the safeher phase III study. Oncologist 23(10):1137–1143.

Lal, A. M., & Anouncia, S. M. (2015). Semi-supervised change detection approach combining sparse fusion and constrained k means for multi-temporal remote sensing images. The Egyptian Journal of Remote Sensing and Space Science, 18(2), 279-288.

Leff, B., Burton, L., Mader, S. L., Naughton, B., Burl, J., Inouye, S. K., ... & Steinwachs, D. (2005). Hospital at home: feasibility and outcomes of a program to provide hospital-level care at home for acutely ill older patients. Annals of internal medicine, 143(11), 798-808.

Lundin, J., Kimby, E., Björkholm, M., Broliden, P. A., Celsing, F., Hjalmar, V., ... & Mellstedt, H. (2002). Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line

treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, The Journal of the American Society of Hematology, 100(3), 768-773.

Luthi F, Fucina N, Divorne N, Santos-Eggimann B, Currat- Zweifel C, Rollier P, Wasserfallen JB, Ketterer N, Leyvraz S (2012) Home care–a safe and attractive alternative to inpatient administration of intensive chemotherapies. Support Care Cancer 20(3):575–581.

Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R. Trastuzumab containing regimens for earlybreast cancer.Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006243.

Palazzani, L. (1996). Il concetto di persona tra bioetica e diritto. Giappichelli.

Payne, J. W., Bettman, J. R., & Johnson, E. J. (1992). Behavioral decision research: A constructive processing perspective. Annual review of psychology, 43(1), 87-131.

Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011; 29:4491-4497.

Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J. H., Davidson, N. E., Geyer Jr, C. E., ... & Wolmark, N. (2011). Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2–positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B31. Journal of clinical oncology, 29(25), 3366.

Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., ... & Cameron, D. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine, 353(16), 1659-1672.

Pivot X, Verma S, Fallowfield L, Muller V, Lichinitser M, Jenkins V, Sanchez Munoz A, Machackova Z, Osborne S, Gligorov J (2017) Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study. Eur J Cancer 86:82–90.

Pivot, X., Romieu, G., Debled, M., Pierga, J. Y., Kerbrat, P., Bachelot, T., ... & Jacquin, J. P. (2013). 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. The lancet oncology, 14(8), 741-748.

Quaderno QS, Bisogni, evidenze ed evoluzione del sistema. Il caso delle formulazioni sottocutanee. Quotidiano Sanità, 2018

Rabec, C., Gonzalez-Bermejo, J., GAVO, C. C. G., Mercy, M., Grassion, L., Pontier, S., ... & Maître, B. (2020). Respiratory support in patients with COVID-19 (outside intensive care unit). A position paper of the Respiratory Support and Chronic Care Group of the French Society of Respiratory Diseases. Respiratory Medicine and Research, 78, 100768.

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer Jr, C. E., Davidson, N. E., ... & Swain, S. M. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine, 353(16), 1673-1684.

Sacchini, V., Pinotti, J. A., Barros, A. C., Luini, A., Pluchinotta, A., Pinotti, M., ... & Borgen, P. I. (2006). Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem?. Journal of the American College of Surgeons, 203(5), 704-714.

Shepperd, S., & Iliffe, S. (2000). Hospital-at-home versus in-patient hospital care: Cochrane Database Systematic Review. 2.

Shepperd, S., Doll, H., Angus, R. M., Clarke, M. J., Iliffe, S., Kalra, L., ... & Wilson, A. D. (2009). Avoiding hospital admission through provision of hospital care at home: a systematic review and meta-analysis of individual patient data. Cmaj, 180(2), 175-182.

Shepperd, S., Gonçalves‐Bradley, D. C., Straus, S. E., & Wee, B. (2016). Hospital at home: home‐based end‐of‐life care. Cochrane Database of Systematic Reviews, (2). Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-1283.

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., ... & Baselga, J. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England journal of medicine, 344(11), 783-792.

Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., ... & Pinter, T. (2011). Adjuvant trastuzumab in HER2-positive breast cancer. New England Journal of Medicine, 365(14), 12731283.

Stilgenbauer, S., Zenz, T., Winkler, D., Buehler, A., Schlenk, R. F., Groner, S., ... & Dreger, P. (2009). Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology, 27(24), 3994-4001.

Strause, J., & Corrie, M. (2013). U.S. Patent No. 8,360,835. Washington, DC: U.S. Patent and Trademark Office.

Taylor, C., Munro, A. J., Glynne-Jones, R., Griffith, C., Trevatt, P., Richards, M., & Ramirez, A. J. (2010). Multidisciplinary team working in cancer: what is the evidence?. Bmj, 340, c951.

Tralongo, P., Ferrau, F., Borsellino, N., Verderame, F., Caruso, M., Giuffrida, D., ... & Gebbia, V. (2011). Cancer patient-centered home care: a new model for health care in oncology. Therapeutics and clinical risk management, 7, 387.

Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., ... & Shak, S. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2overexpressing metastatic breast cancer. Journal of Clinical Oncology, 20(3), 719-726.